期刊文献+

表皮生长因子受体和环氧化酶-2在前列腺癌中的共同表达和意义 被引量:3

Co-exprssion of EGFR and COX-2 and their significance in prostate cancer
下载PDF
导出
摘要 目的:探讨表皮生长因子受体(Epidermal growthfactor receptor,EGFR)和环氧化酶-2(Cyclooxygenase-2,COX-2)在前列腺癌(Prostate cancer,PCa)中的共同表达和临床意义。方法:采用免疫组织化学法(SP)测定48例PCa中EGFR和COX-2阳性表达情况,按免疫组织化学结果分为EGFR(-)COX-2(-)、EGFR(-)COX-2(+)、EGFR(+)COX-2(-)和EGFR(+)COX-2(+)四组,分析它们表达与临床病理和预后的关系。结果:EGFR、COX-2阳性在PCa中为34例(70.8%)、21例(45.8%),两者的表达在PCa中无相关性(r=0.04,P=0.80),EGFR和COX-2共同表达有16例(33.3%),和Gleason评分、PSA水平有关(P<0.05),5年复发率83.1%,显著高于EGFR(+)COX-2(-)(27.8%)、EGFR(-)COX-2(+)(16.7%)和EGFR(-)COX-2(-)(12.5%)(P<0.05);13例转移PCa中有10例为EGFR(+)COX-2(+)(62.5%),显著高于其他三组(P<0.05)。结论:EGFR和COX-2在PCa中表达无相关性,但其共同表达可以作为判断PCa预后的重要标志。 Objective:To explore the co-expression of epidermal growth factor receptor(EGFR)and cyclooxygenase-2(COX-2) as well as their clinic significance in prostate cancer. Methods:Protein expression of EGFR and COX-2 in formalin-fixed and paraffin-embedded blocks of 48 PCa tissues was analyzed by immunohistochemical method and then were divided into four groups : EGFR ( - ) COX-2 ( - ) ; EGFR ( - ) COX-2 ( + ) ; EGFR ( ) COX-2 ( - ) ; EGFR ( + ) COX-2 ( + ). Results: Positive rate of EGFR and COX-2 expression in PCa was 70.8% and 45.8% ,There was no relationship between EGFR and COX-2 expression(r=0.04 ,P=0.80). Co-exprssion of EGFR and COX-2 was shown in 16 PCa tissues (33.3%). There was statistically positive correlation with high Gleason score and PSA. Of the patients in four groups ,patients positive for both EGFR and COX-2 proteins was found to higher in 5-year recurrence rate(83.1%) compared, with 27.8% for EGFR(+)COX-2(-),16.7% for EGFR (-)COX-2(+) ,12. 5% for EGFR(-)COX-2(-). There was 10 co-exprssion of EGFR and COX-2 in 13 metastasis PCa while only 3 in other three groups(P〈0.05). Conclusions: There was no relationship between EGFR and COX-2 expression in PCa, but their co-expression maybe serve as a new important of prognostic marker.
出处 《临床泌尿外科杂志》 2008年第4期283-285,288,共4页 Journal of Clinical Urology
关键词 前列腺癌 表皮生长因子受体 环氧化酶-2 共同表达 Prostate cancer Epidermal growth factor receptor Cyclooxygenase-2 Co-expression
  • 相关文献

参考文献12

  • 1Shadan All, Basil F, El-Rayes, et al. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy [J]. Mol Cancer Ther, 2005, 4(12):1943-1951.
  • 2Han C, Michalopoulos G K, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR /MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells [J]. J Cell Physiol, 2006, 207:261-270.
  • 3Soo R, Putti T, Tao Q, et al. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression [J]. Arch Otolaryngol Head Neck Surg, 2005, 13 : 147-52.
  • 4Gwi Eon Kim, Yong Bae Kim,Nam Hoon Cho,et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: A potential predictor of poor survival[J]. Clinical Cancer Research, 2004, 10: 1366-1374.
  • 5Di I.orenzo G, Tortora G D, Armiento E P, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer[J]. Clin Cancer Res, 2002, 8: 3438-3444.
  • 6Mi Sun Choe, Xin Zhang, Hyung Ju, et al. Interaction between epidermal growth factor receptor and cyclooxygenase 2mediated pathways and its implications for the chernoprevent. tion of head and neck cancer[J]. Mol Cancer Ther, 2005,4:1448-1455.
  • 7Choen BL, Gomez P, Omori Y, et al. Cyclooxygenase- 2 (COX-2) expression is a independent predictor of prostate cancer recurrence[J]. Int J Cancer, 2006, 119: 1082-1087.
  • 8Yoon J H, Higuchi H, Werneburg N W, et al. Bile acids induce cyclooxygenase-2 expression via epidermal growth factor receptor in a human cholangiocarcinoma cell line [J]. Gastroen-terology, 2002, 122: 985-993.
  • 9Shen S C, Ko C H, Hsu K C, et al. 3-OH flavone inhibition of epidermal growth factor induced proliferaton through blocking prostaglandin E2 production[J]. Int J Cancer, 2004, 108: 502-510.
  • 10Pal R, Soreghan B, Szabo I L, et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy[J]. Nat Med, 2002, 8:289-293.

同被引文献23

  • 1薛洁,谢梅林,顾振纶,张克平.丹参和山楂提取物含药血清对胆固醇代谢的影响[J].中草药,2007,38(1):73-77. 被引量:22
  • 2蔡海霞,祝光礼(指导).中药抗动脉粥样硬化实验研究进展[J].浙江中西医结合杂志,2007,17(5):328-330. 被引量:3
  • 3Ando H,Tsuruoka S, Yamamoto H, et al. Effects of pravastatin on the expression of ATP-binding cassette transporter[J]. J Pharmacol Exp Ther,2004,311 ( 1 ) :420-425.
  • 4Cao WM, Murao K, Imachi H, et al. Insulin-like growth factor-i regulation of hepatic scavenger receptor class[J]. Endocrinology,2004,145(12) :5540 5547.
  • 5Hinestrosa MC,Dickersin K,Klein P,et al.Shapingthe future of biomarker research in breast cancer to en-sure relevance[J].Nature Reviews Cancer,2007,7:311-315.
  • 6Tavassoli FA,Devilee P.World Health Organizationclassification of tumours:pathology and genetics oftumours of the breast and female genital organs[M].Lyon:IARC Press,2003.
  • 7Burnside ES,Sickles EA,Bassett LW,et al.The ACRBI2RADS experience:learning from history[J].Journalof the American College of Radiology,2009,6(12):851-860.
  • 8Liakakos T,Xeropotamos N,Ziogas D.EGFR as aprognostic marker for gastric cancer[J].World J Surg,2008,32(6):1225-1226.
  • 9Ciardiello F,Tortora G.EGFR antagonists in cancertreatment[J].N Engl J Med,2008,358(11):1160-1174.
  • 10贾连群,王启明,柳春,田丽,傅明德.高密度脂蛋白亚类抗脂多糖作用的研究[J].细胞与分子免疫学杂志,2007,23(7):616-619. 被引量:7

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部